Merdad Parsey Sells 2,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILDGet Free Report) insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Merdad Parsey also recently made the following trade(s):

  • On Wednesday, February 28th, Merdad Parsey sold 2,000 shares of Gilead Sciences stock. The stock was sold at an average price of $73.18, for a total value of $146,360.00.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.79 during trading hours on Tuesday, reaching $72.09. 6,138,241 shares of the company were exchanged, compared to its average volume of 7,529,001. Gilead Sciences, Inc. has a fifty-two week low of $71.37 and a fifty-two week high of $87.86. The stock’s fifty day moving average is $74.46 and its two-hundred day moving average is $77.20. The company has a market cap of $89.76 billion, a price-to-earnings ratio of 16.20, a P/E/G ratio of 0.93 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the previous year, the company posted $1.67 earnings per share. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.27%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently bought and sold shares of the business. PCA Investment Advisory Services Inc. acquired a new position in Gilead Sciences in the second quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new position in Gilead Sciences in the third quarter valued at approximately $26,000. Tompkins Financial Corp lifted its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. Union Savings Bank acquired a new position in Gilead Sciences in the second quarter valued at approximately $29,000. Finally, Fortitude Family Office LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Wells Fargo & Company reduced their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. Barclays cut their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Finally, Oppenheimer lowered their target price on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and an average target price of $85.36.

Check Out Our Latest Analysis on GILD

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.